Abstract
CD166 has been identified as an important cancer stem cell (CSC) marker in colorectal cancer (CRC). The purpose of our study was to investigate the relationship between CD166 expression and clinical features and to examine the role of CD166 expression on the survival of patients with CRC. A total of 15 studies with 3,332 cases were identified in this meta-analysis. The pooled OR indicated that CD166 expression was significantly higher in CRC than in colonic adenomas or normal colonic mucosa (OR = 3.48, P = 0.002 and OR = 55.13, P = 0.017, respectively). CD166 expression was found to be negatively correlated with vascular invasion (OR = 0.75, P = 0.017), but it was not associated with gender, tumor location, lymph node status, distant metastasis, clinical stage, T classification or tumor differentiation. Meanwhile, CD166 expression was not associated with the prognosis of overall survival (OS) (HR = 1.20, 95% CI = 0.45-3.22, P = 0.72) in multivariate regression analysis. One study reported that CD166 expression may be a predictor of survival in stage II CRC patients using multivariate logistic regression analysis (OS: OR = 9.97, P = 0.035; disease-specific survival: OR = 29.02, P = 0.011). Our findings suggest that CD166 expression may be correlated with CRC carcinogenesis and a decreased risk of vascular invasion, and it may become a predictive biomarker of survival for stage II CRC patients, but additional studies with large sample sizes are essential to validate the prognostic and predictive values of CD166 expression.
Highlights
Worldwide, colorectal cancer (CRC) is one of the most frequent malignant tumors and the fourth leading cause of cancer-related deaths in human cancers
Our findings suggest that CD166 expression may be correlated with CRC carcinogenesis and a decreased risk of vascular invasion, and it may become a predictive biomarker of survival for stage II CRC patients, but additional studies with large sample sizes are essential to validate the prognostic and predictive values of CD166 expression
Our meta-analysis suggested that CD166 expression is associated with the carcinogenesis of CRC and a decreased risk of patients with vascular invasion
Summary
Colorectal cancer (CRC) is one of the most frequent malignant tumors and the fourth leading cause of cancer-related deaths in human cancers. Some studies have shown that CSCs are responsible for the carcinogenesis, progression, metastasis and prognosis of human cancers [6,7,8]. CD166 expression is closely correlated with various types of www.impactjournals.com/oncotarget human cancers, including CRC [16,17,18]. A significant correlation between CD166 expression and overall survival (OS) of patients was reported based on multivariate analysis by Weichert et al [19]. Ribeiro et al reported that CD166 expression was not related to OS of patients with CRC using multivariate analysis [20]. We evaluated the prognostic and predictive role of CD166 expression in CRC patients with multivariate analysis. We analyzed the correlation of CD166 expression with clinicopathological characteristics in this study
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
